(Q38854176)

7 September 2017

title

Efficacy and safety of pegylated interferon in children and adolescents infected with chronic hepatitis C: a preliminary study (English)

1 reference

7 September 2017

1 reference

1 reference

1 reference

Omaima N El-Gazayerly

1 reference

ORCID Public Data File 2021

author name string

Doa'a Hamed Abdel-Aziz

1

1 reference

7 September 2017

Nirmeen Ahmed Sabry

2

1 reference

7 September 2017

Manal Hamdy El-Sayed

3

1 reference

7 September 2017

Omima Naiem El-Gazayerly

4

1 reference

7 September 2017

publication date

2 April 2010

1 reference

Journal of Pharmacy Practice

7 September 2017

published in

1 reference

7 September 2017

volume

24

1 reference

7 September 2017

issue

2

1 reference

7 September 2017

page(s)

203-210

1 reference

Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975.

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

Hepatitis C antibody prevalence in blood donors in different governorates in Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

21 January 2018

Therapy of Hepatitis C

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

Interferon-alpha for viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

Does interferon and ribavirin combination therapy increase the rate of treatment response in children with hepatitis C?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190010367737

21 January 2018

Identifiers

DOI

10.1177/0897190010367737

1 reference

7 September 2017

1 reference